{
    "clinical_study": {
        "@rank": "25324", 
        "arm_group": {
            "arm_group_label": "Treatment (decitabine)", 
            "arm_group_type": "Experimental", 
            "description": "Patients receive decitabine IV over 30 minutes on days 1-5 weekly for 4 weeks. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity.\nCohorts of 3-6 patients receive escalating doses of decitabine until the MTD is determined. The MTD is defined as the dose preceding that at which at least 2 of 3 or 2 of 6 patients experience dose-limiting toxicity."
        }, 
        "brief_summary": {
            "textblock": "This phase I trial is studying the side effects and best dose of decitabine in treating\n      patients with advanced solid tumors that have not responded to previous treatment. Drugs\n      used in chemotherapy use different ways to stop tumor cells from dividing so they stop\n      growing or die"
        }, 
        "brief_title": "Decitabine in Treating Patients With Advanced Solid Tumors", 
        "condition": [
            "Male Breast Cancer", 
            "Recurrent Bladder Cancer", 
            "Recurrent Breast Cancer", 
            "Recurrent Melanoma", 
            "Stage III Melanoma", 
            "Stage IV Bladder Cancer", 
            "Stage IV Breast Cancer", 
            "Stage IV Melanoma", 
            "Unspecified Adult Solid Tumor, Protocol Specific"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Urinary Bladder Neoplasms", 
                "Breast Neoplasms", 
                "Melanoma", 
                "Breast Neoplasms, Male"
            ]
        }, 
        "detailed_description": {
            "textblock": "PRIMARY OBJECTIVES:\n\n      I. Determine the maximum tolerated dose of decitabine in patients with advanced solid\n      tumors.\n\n      II. Determine the toxic effects of this drug in these patients. III. Determine the dose of\n      this drug with biologic activity in these patients. IV. Determine the pharmacokinetics of\n      this drug in these patients. V. Determine clinical response to this drug in these patients.\n\n      OUTLINE: This is a dose-escalation, multicenter study.\n\n      Patients receive decitabine IV over 30 minutes on days 1-5 weekly for 4 weeks. Courses\n      repeat every 6 weeks in the absence of disease progression or unacceptable toxicity.\n\n      Cohorts of 3-6 patients receive escalating doses of decitabine until the maximum tolerated\n      dose (MTD) is determined. The MTD is defined as the dose preceding that at which at least 2\n      of 3 or 2 of 6 patients experience dose-limiting toxicity.\n\n      Patients are followed at 2 weeks."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Diagnosis of advanced metastatic solid tumor for which all standard therapy has\n             failed, including, but not limited to the following:\n\n               -  Stage III or IV melanoma\n\n                    -  Mucosal melanoma allowed\n\n                    -  No resectable stage III melanoma\n\n               -  Bladder cancer\n\n               -  Breast cancer\n\n          -  No active symptomatic CNS disease\n\n          -  No radiographically evident cerebral edema\n\n          -  Hormone receptor status:\n\n               -  Not specified\n\n          -  Male or female\n\n          -  Performance status - ECOG 0-1\n\n          -  Hemoglobin at least 9.0 g/dL\n\n          -  Platelet count at least 100,000/mm^3\n\n          -  WBC at least 3,500/mm^3\n\n          -  Absolute granulocyte count at least 1,500/mm^3\n\n          -  No coagulation disorders\n\n          -  Bilirubin no greater than 1.5 times upper limit of normal (ULN)\n\n          -  SGOT and SGPT less than 2.5 times ULN\n\n          -  Hepatitis B surface antigen negative\n\n          -  Hepatitis C antibody negative\n\n          -  Creatinine no greater than 1.5 times ULN\n\n          -  No major cardiovascular system illness\n\n          -  No major respiratory system illness\n\n          -  Not pregnant or nursing\n\n          -  Negative pregnancy test\n\n          -  Fertile patients must use effective contraception\n\n          -  HIV negative\n\n          -  No major systemic infection\n\n          -  At least 1 month since  prior radiotherapy\n\n          -  At least 1 month since any prior anticancer therapy or adjuvant therapy\n\n          -  No other experimental treatment within 30 days prior to, during, and for 30 days\n             after study therapy"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "24", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "February 14, 2002", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00030615", 
            "org_study_id": "NCI-2012-02727", 
            "secondary_id": [
                "OC-01-01", 
                "U01CA062505", 
                "CDR0000069182"
            ]
        }, 
        "intervention": [
            {
                "arm_group_label": "Treatment (decitabine)", 
                "description": "Given IV", 
                "intervention_name": "decitabine", 
                "intervention_type": "Drug", 
                "other_name": [
                    "5-aza-dCyd", 
                    "5AZA", 
                    "DAC"
                ]
            }, 
            {
                "arm_group_label": "Treatment (decitabine)", 
                "description": "Correlative studies", 
                "intervention_name": "pharmacological study", 
                "intervention_type": "Other", 
                "other_name": "pharmacological studies"
            }, 
            {
                "arm_group_label": "Treatment (decitabine)", 
                "description": "Correlative studies", 
                "intervention_name": "laboratory biomarker analysis", 
                "intervention_type": "Other"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Decitabine"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "February 6, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Los Angeles", 
                    "country": "United States", 
                    "state": "California", 
                    "zip": "90033-0804"
                }, 
                "name": "University of Southern California"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase I Study Of The Toxicities, Biologic And Clinical Effects Of Daily 5 Aza 2'Deoxycytidine (DAC), NSC 127716 (IND 50733) For Four Weeks In Patients With Advanced Malignancies", 
        "overall_official": {
            "affiliation": "University of Southern California", 
            "last_name": "Jeffrey Weber", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "September 2008", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Maximum tolerated dose determined by dose-limiting toxicities graded according to CTC 2.0 toxicity criteria", 
            "safety_issue": "Yes", 
            "time_frame": "6 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00030615"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "National Cancer Institute (NCI)", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "National Cancer Institute (NCI)", 
                "agency_class": "NIH"
            }
        }, 
        "start_date": "December 2001", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2013"
    }, 
    "geocoordinates": {
        "University of Southern California": "34.052 -118.244"
    }
}